Participants will each receive a single intravenous infusion of AFTX-201 at doses determined from preclinical studies.
Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results